Back

Severity of chronic obstructive pulmonary disease and risk of one-year mortality after first-time implantation of implantable cardioverter defibrillator: a nationwide study

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Real-world data in ICD treatment Implantable Cardioverter-Defibrillator (ICD) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Amna Alhakak

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
Driving restrictions following defibrillator implantation significantly affect recipients' ability to maintain employment
Doctor J. Bjerre (Hilleroed, DK)
Abstract Slides
Presentation thumbnail
History of betablocker treatment breaks and risk of ventricular tachyarrhythmias among patients with heart failure and implantable cardioverter defibrillator: a nationwide cohort study
Miss E. Mc Evoy Kjaer (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Effect of defibrillator on long term all-cause mortality in patients with chronic kidney disease: an updated meta-analysis
Doctor F. Aslam (Stony Brook, US)
Abstract Slides
Presentation thumbnail
The role of trigger factors in the occurrence of appropriate ICD shocks and their prognostic implications
Doctor T. Kleemann (Ludwigshafen, DE)
Abstract Slides
Presentation thumbnail
The case against premature treatment of heart failure patients with implantable cardioverter-defibrillators: results from an institutional registry
Doctor I. Prepolec (Zagreb, HR)
Abstract Slides

Access the full session

Session thumbnail
Real-world data in ICD treatment

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Implantable cardioverter-defibrillator
thumbnail
Congress Presentation
When to consider device therapy in HFrEF - discussion
thumbnail
Congress Session
Debate on primary prevention in ICD therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources